Intech Biopharm Corporation (TPEX:6461)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
18.00
-0.05 (-0.28%)
Apr 29, 2026, 1:17 PM CST
-1.37%
Market Cap 3.22B
Revenue (ttm) 107.53M
Net Income (ttm) -389.03M
Shares Out 178.41M
EPS (ttm) -2.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 79,113
Average Volume 228,979
Open 18.35
Previous Close 18.05
Day's Range 18.00 - 18.35
52-Week Range 14.10 - 26.25
Beta 0.27
RSI 42.56
Earnings Date May 12, 2026

About Intech Biopharm

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 90
Stock Exchange Taipei Exchange
Ticker Symbol 6461
Full Company Profile

Financial Performance

In 2025, Intech Biopharm's revenue was 107.53 million, an increase of 170.31% compared to the previous year's 39.78 million. Losses were -389.03 million, 5.66% more than in 2024.

Financial Statements

News

There is no news available yet.